Alnylam Pharmaceuticals

$169.69
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.28 (-0.75%) As of 4:01 PM UTC today

Why Robinhood?

You can buy or sell ALNY and other stocks, options, and ETFs commission-free!

About ALNY

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA. The listed name for ALNY is Alnylam Pharmaceuticals, Inc. Common Stock.

CEO

John M. Maraganore

Employees

1,323

Headquarters

Cambridge, Massachusetts

Founded

2002

Market Cap

19.50B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.21M

High Today

$172.54

Low Today

$169.00

Open Price

$172.54

Volume

90.86K

52 Week High

$175.41

52 Week Low

$84.97

Collections

Analyst Ratings

67%

of 24 ratings

Buy

67%

Hold

33%

Sell

ALNY Earnings

-$2.23

-$1.49

-$0.74

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 4, Pre-Market